Preoperative marker for diagnosis and differentiation of renal carcinoma.

Center name Тестовый центр
Summary A German university has developed a marker for non-invasive diagnosis and differentiation of benign and malignant renal carcinoma. An unequivocal differentiation will improve the planning of the adequate treatment. The university offers a license agreement.
Description of the offer Kidney cancer is classified as malignant tumors originating from different renal cells with several subtypes. The cells of these subtypes can mimic a benign kidney tumor, called oncocytomas. The unequivocal differentiation is essential for planning the adequate operative procedure and the patient follow-up monitoring (which is not necessary for oncocytomas). To date, it is not possible to reliably differentiate between malignant subtypes and benign kidney tumors by means of the available antibody panel and imaging methods. A German university found a splice isoform of Vimentin, namely Vimentin3 (Vim3), as an indicator of benign oncocytomas. Renal cell carcinomas (RCCs) are negative for Vim3. They also discovered a truncated variant of the protein MAPK p38, namely Mxi-2, which indicates RCC, including all subtypes. Oncocytomas, however, is negative for Mxi-2. Both markers are detectable by means of monoclonal antibodies directed against Vim3 and Mxi-2 in body fluids, such as urine, as well as in tissue. Detection of both markers in urine makes it possible for the first time to provide urologists and oncologists with a non-invasive test for a pre-operative diagnosis so as to appropriately treat the patient and plan the follow-up. The marker is also usable for routine medical check-ups (for persons aged 55 and above). The university offers a license agreement to companies from the diagnostic industry. The partner should cooperate to further develop the prototype to a final product.
Advantages and Innovations The identified vimentim3 represents a novel approach to differentiate a benign oncocytoma from malignant carcinomas. Apart from the fact that this procedure will improve the diagnosis it will also optimize the treatment of the patients.
Current Stage of Development - Urine quick test is in development. - Monoclonal antibodies designed for use.
Technological Keywords 06001003 Cytology, Cancerology, Oncology
06001005 Diagnostics, Diagnosis
Market Keywords 05001003 Differential diagnosis
05005014 Oncology
Copyright Patent(s) applied for but not yet granted
Comments Regarding IPR Status A European and US-American patent has been filed.
Type of Partnership Required License Agreement
Type and Role of Partner Sought The university offers a license agreement Potential licensees come from the diagnostic industry. Especially those companies that offer immunohistochemical analyses and investigations in body fluids (by means of antibody detection) are addressed, specifically urine diagnostics. The cooperation would include the further development to a ready to use product. This involves the relevant studies. Meanwhile the prototype is under development (test strip and ELISA test).
Date of creation 23.03.2018
Profile type Technology offer
Profile openness to interact Y
Profile from EEN Y

Этот сайт использует «cookies» и собирает следующие данные в целях улучшения его работы (Yandex Metrika, Google Analytics) : IP-адрес компьютера, страна, дата и время посещения, тип браузера, тип операционной системы, модель мобильного устройства, тип устроиства. Для продолжения работы с сайтом нажмите: «Согласен(на)»